ReviewFrontiers in veterinary science2026
Snake envenomation in veterinary medicine: comparative insights and emerging therapies.
Review in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Snakebite envenomation poses a significant threat to both public health and animal welfare, resulting in substantial human suffering and economic burden worldwide. Recognized by the World Health Organization as a neglected tropical disease, snakebites disproportionately affect impoverished rural regions across Africa, Asia, and South America, with an estimated 2.7 million envenomations and 81,000-138,000 deaths annually. In veterinary medicine, snakebites are similarly impactful, with up to 300,000 animals affected each year in the United States alone-primarily dogs and cats-while global veterinary cases likely number in the millions. Despite this, snakebites remain non-notifiable diseases, contributing to significant underreporting. The economic implications are profound, with treatment costs for human victims exceeding $200,000 per case and veterinary care ranging from $8,000 to $50,000 per case, often surpassing the financial capacity of pet owners. Beyond acute care, long-term sequelae such as chronic neuropathy and tissue damage further compound the burden. Current literature is limited in comparative analyses of envenomation mechanisms across species, particularly in livestock. This review will create a deeper understanding of pathophysiology, treatment modalities, and emerging therapies. Understanding of this background is essential to further advancements in science surrounding snake envenomation in both human and veterinary species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.